Monitoring of cellular resistance to cancer chemotherapy

Hematology/Oncology Clinics of North America

Volumn 16, Issue 2, 2002, Pages 357-372

  Krishan, Awtar ^a   Arya, Poonam ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYCLOSPORIN DERIVATIVE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; RIBONUCLEOPROTEIN; TUMOR PROTEIN; VALSPODAR; ANTHRACYCLINE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; FLUOROCHROME; PHENOTHIAZINE DERIVATIVE; PROTEIN; UNCLASSIFIED DRUG; VERAPAMIL;

CANCER STEM CELL; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MULTIDRUG RESISTANCE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW; CANCER CHEMOTHERAPY; DRUG MONITORING; DRUG RETENTION; DRUG TRANSPORT; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; TUMOR STEM CELLS; VAULT RIBONUCLEOPROTEIN PARTICLES; HUMAN;

EID: 0036080406     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(01)00016-8     Document Type: Review

References (77)

1. Drug resistance: Genotype versus phenotype
2. Clinical trials of agents that reverse multidrug resistance
3. P-glycoprotein and resistance to anticancer drugs
4. Multifactorial resistance to adriamycin: Relationship of DNA repair glutathione transferase activity drug efflux and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia
5. Anthracycline resistance in murine leukemic P388 cells: Role of drug efflux and glutathione-related enzymes
6. Flow cytometric studies of intracellular adriamycin in single cells in vitro
7. Effect of drug efflux blockers on vital staining of cellular DNA with Hoechst 33341
8. Monitoring of cellular resistance to cancer chemotherapy: Drug retention and efflux
9. Cell cycle related phenothiazine effects on adriamycin transport
10. Drug retention efflux and resistance in tumor cells
11. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines
12. Flow cytometric analysis of the multiple drug resistance phenotype
13. A comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells
14. Flow cytometric studies on modulation of cellular adriamycin retention by phenothiazines
15. Patterns of anthracycline retention modulation in human tumor cells
16. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells
17. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
18. Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response
19. Reversal of resistance to rhodamine 123 in adriamycin-resistant Friend leukemia cells
20. Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance
21. Calcein accumulation as a fluorometric functional assay of the multidrug transporter
22. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter
23. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
24. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A southwest oncology group study
25. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation retention and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells
26. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma
27. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
28. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
29. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug resistant breast cancer cells is NCA the nonspecific cross-reacting antigen of carcinoembryonic antigen
30. The drug resistance related protein LRP is the human major vault protein
31. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia
32. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: No evidence of prognostic impact in follow-up
33. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy relapse rate and overall survival in acute leukemia
34. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer
35. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood
36. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies
37. Monoclonal antibody JSB-1 detects a highly conserved epitope on the p-glycoprotein associated with multidrug resistance
38. Specific detection of multidrug resistance proteins MRP1 MRP2 MRP3 MRP5 and MDR3 P-glycoprotein with a panel of monoclonal antibodies
39. Evaluation of multidrug resistant phenotype by flow cytometry with monoclonal antibodies and functional tests
40. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
41. Carrier-mediated uptake of rhodamine 123: Implications on its use for MDR research
42. Novel gallium (III) complexes transported by MDR1 P-glycoprotein: Potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo
43. Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function
44. Disconcordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia
45. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia
46. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR)reversal in adult soft tissue sarcoma
47. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
48. A phase I study of induction chemotherapy for older patients with diagnosed acute myeloid leukemia (AML) using mitoxantrone etoposide and the mdr modulator PSC 833: A southwest oncology group study
49. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
50. Combined action of PSC 833 (Valspodar) a novel MDR reversing agent with mitoxantrone etoposide and cytarabine in poorprognosis acute myeloid leukemia
51. Function evolution and structure of multidrug resistance protein (MRP)
52. Overexpression of multidrug resistance associated protein (MRP) increases resistance to natural product drugs
53. Structural mechanistic and clinical aspects of MRP1
54. Transport of glutathione glucuronate and sulfate conjugates by the MRP gene-encoded conjugate export pump
55. Characterization of the Mr 190, 000 multidrug resistance protein (Mrp) in drug-selected and transfected human tumor cells
56. Multidrug resistance-associated protein: A protein distinct from P-glycoprotein involved in cytotoxic drug expulsion
57. Analysis of expression of cMOAT (MRP2) MRP3 MRP4 and MRP5 homologues of the multidrug resistance-associated protein gene (MRP1) in human cancer cell lines
58. Novel mechanisms of drug resistance in leukemia
59. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small lung cancer cells
60. Functional detection of MDR1/p170 and MRP/p190-mediated multidrug resistance in tumor cells by flow cytometry
61. Tissue distribution of the multidrug resistance protein
62. Optimal immunocytochemical and flow cytometric detection of P-gp MRP and LRP in childhood acute lymphoblastic leukemia
63. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response
64. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung
65. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporin for reversal of P-glycoprotein
66. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy
67. Overexpression of a Mr 110.000 vesicular protein in non p-glycoprotein mediated multidrug resistance
68. Broad distribution of the multidrug resistance-related vault lung protein in normal human tissues and tumors
69. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
70. Frequency and clinical significance of the expression of multi drug resistance proteins MDR1/P-gp MRP1 and LRP in acute myeloid leukemia. A southwest oncology group study
71. A multidrug resistance transporter from human MCF-7 breast cancer cells
72. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter MXR (ABCG2)
73. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
74. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
75. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
76. A functional assay for detection of the mitoxantrone resistance protein MXR(ABCG2)
77. Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas